SCHEMBL17320995

SCHEMBL17320995

CCn1nc(COS(C)(=O)=O)cc1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.35
▸ RPS6KB1 P23443 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ EPHX2 P34913 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ ADORA2A P29274 2/20 0.33
▸ ADORA2B P29275 2/20 0.33
▸ GLS O94925 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ MEN1 O00255 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ FPR3 P25089 1/20 0.30
▸ FPR2 P25090 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17320990 0.83 CYP1A2 (0.32) CYP1A2CYP3A4CYP2D6
SCHEMBL15898854 0.81 AURKA (0.32) AURKALMNACYP1A2CYP3A4CYP2D6
SCHEMBL4364406 0.81 BCHE (0.41) LMNASMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL15746138 0.75 GAA (0.36) LMNASMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL12126163 0.75 ADORA2A (0.36) AURKARPS6KB1LMNAEPHX2ADORA2A
SCHEMBL6105512 0.72 ADORA2A (0.42) AURKARPS6KB1LMNASMN1; SMN2EPHX2
SCHEMBL22445335 0.70 CYP1A2 (0.31) CYP1A2CYP3A4CYP2D6
SCHEMBL21805823 0.69 NPY5R (0.38) ALDH1A1MAPT
SCHEMBL30088013 0.69 NPY5R (0.38) ALDH1A1MAPT
SCHEMBL17324207 0.69 PTGS2 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353544-A1 NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353544-A1 NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 AURKA 1210/4885RPS6KB1 288/4885LMNA 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback